Skip to nav Skip to content

Clinical Trial Search

296 Clinical Trials Found

Clinical Trial 21887

A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes
Disease Site: Leukemia, other
PI: Padron, Eric

Clinical Trial 21143

Disease Site: Mycosis Fungoides
PI: Sokol, Lubomir

Clinical Trial 21626

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
Disease Site: Lung
PI: Gray, Jhanelle

Clinical Trial 21634

A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
Disease Site: Non-Hodgkin's Lymphoma
PI: Bello, Celeste

Clinical Trial 20938

A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-Small Cell Lung Cancer (NSCLC) with Primary Tumors Between 1-4 cm
Disease Site: Lung
PI: Chiappori, Alberto

Clinical Trial 21140

Disease Site: Larynx, Lip, Oral Cavity and Pharynx
PI: Caudell, Jimmy

Clinical Trial 20955

A Phase II Study of Binimetinib plus Belinostat for Subjects with Metastatic Uveal Melanoma
Disease Site: Other Skin
PI: Tarhini, Ahmad

Clinical Trial 21415

Disease Site: Other Hematopoietic
PI: Kuykendall, Andrew

Clinical Trial 22080

An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma
Disease Site: Non-Hodgkin's Lymphoma
PI: Chavez, Julio

Clinical Trial 21056

Disease Site: Lymphoid Leukemia
PI: Sandoval-Sus, Jose

Clinical Trial 20923

A Phase I/II Trial of Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
Disease Site: Leukemia, other, Myeloid and Monocytic Leukemia
PI: Elmariah, Hany

Clinical Trial 20494

A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy
Disease Site: Melanoma, skin
PI: Tarhini, Ahmad